Prosecution Insights
Prosecution Insights
Technology areas: Chemistry & Materials • Medical Devices & Mechanical Engineering
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Qidni Labs Inc. is navigating 3 pending office actions in the Medical Devices & Mechanical Engineering technology area. These actions are spread across 2 distinct art units, showing that the company's technical disclosures bridge multiple specialized groups within the patent office. The involvement of 3 distinct examiners indicates that each pending action is currently being handled by a different individual. This structure suggests that the company's patent strategy is currently facing a broad range of individual examiner perspectives.
DAKKAK, JIHAD is the busiest examiner assigned to this portfolio, currently overseeing 1 pending office action. Because the 3 pending office actions are distributed among 3 distinct examiners, the company faces a variety of examination styles. Practitioners should note that while the work is concentrated in 2 distinct art units, the individual examiner assignments are decentralized across the pending matters. This requires the applicant to maintain a flexible strategy that can adapt to the specific requirements of different officials at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAKKAK, JIHAD | 1 | 49.3% | +46.0% |
| KIM, SUN U | 1 | 78.2% | +11.5% |
| YANG, CHENG FONG | 1 | 62.8% | +22.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906543 | BLOOD TREATMENT SYSTEM AND METHODS OF CONTROLLING SAME | DAKKAK, JIHAD | — |
| 17904662 | PORTABLE AND WEARABLE DRUG DELIVERY SYSTEM | KIM, SUN U | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906543 | BLOOD TREATMENT SYSTEM AND METHODS OF CONTROLLING SAME | DAKKAK, JIHAD | — |
| 17904662 | PORTABLE AND WEARABLE DRUG DELIVERY SYSTEM | KIM, SUN U | — |
| 17594156 | SORBENT FOR USE IN RENAL THERAPY | YANG, CHENG FONG | — |
| Art Unit | Apps |
|---|---|
| 3781 | 2 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17906543 | BLOOD TREATMENT SYSTEM AND METHODS OF CONTROLLING SAME | DAKKAK, JIHAD | 3781 | §102§103 | Final Rejection | — | Pending | Sep 16, 2022 |
| 17904662 | PORTABLE AND WEARABLE DRUG DELIVERY SYSTEM | KIM, SUN U | 1777 | §102§103§112 | Non-Final OA | — | Pending | Aug 19, 2022 |
| 17594156 | SORBENT FOR USE IN RENAL THERAPY | YANG, CHENG FONG | 3781 | §103 | Final Rejection | — | Pending | Oct 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial